Form 4: Century Therapeutics Executive Sells Shares for Tax Withholding

Century Therapeutics SVP Finance & Operations Douglas Carr sold company shares to cover tax withholding obligations upon vesting of restricted stock units.

Summary

• Douglas Carr, SVP Finance & Operations at Century Therapeutics, Inc., reported a transaction on June 8, 2026.
• The transaction involved the sale of 249 shares of common stock.
• These shares were sold to cover tax withholding obligations related to the vesting of restricted stock units.
• The sale was automatic and not at the discretion of Mr. Carr.
• Following the transaction, Mr. Carr beneficially owns 506,748 shares of common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale is purely for tax withholding purposes and not indicative of the executive's confidence in the company's future performance.

Positives

• The sale was an automatic process to cover tax obligations, indicating no discretionary selling pressure from management.
• The executive still beneficially owns a significant number of shares (506,748) after the transaction.

Negatives

• A portion of the executive's vested equity was sold, which could be perceived negatively by the market, although it was for tax purposes.

Future Outlook

No specific future outlook or guidance is provided in this filing.

Management Comments

• "The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units."
• "Such sales were automatic and not at the discretion of the Reporting Person."

Industry Context

StockSavvy.ai notes that insider sales for tax withholding are common events, especially upon the vesting of equity awards. While not indicative of a negative view on the company's prospects, such transactions can sometimes create short-term selling pressure.

Stakeholder Impact

• Shareholders: The sale of 249 shares is a very small number relative to the total outstanding shares and is unlikely to have a significant impact on the stock price. It is a standard event for equity compensation.

Key Dates

Keywords

Century Therapeutics, IPSC, Form 4, Insider Transaction, Stock Sale, Tax Withholding, Restricted Stock Units, Executive Compensation